Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
B
Brendan Frett
High Impact
Assistant Professor
Also affiliated: University of Arizona (2012–2020); University of Arizona Cancer Center (2014)
Pharmaceutical Science, College of Pharmacy
24 h-index
136 pubs
1,491 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Brendan Frett is an Assistant Professor in Pharmaceutical Science at the University of Arkansas for Medical Sciences. His research focuses on translational drug discovery and development, with the goal of translating laboratory findings into patient treatments. Dr. Frett's work has involved the transfer of academic discoveries to pharmaceutical companies for clinical advancement.
His research interests include the design and synthesis of novel small molecule inhibitors targeting specific cellular pathways implicated in cancer. This has led to publications on targeting mutant KRAS, NEK2, and tropomyosin receptor kinases (TRKs) for anticancer therapeutics, as well as the development of pan-RET/VEGFR2 kinase inhibitors. Dr. Frett's work also encompasses structure-activity relationship studies and the synthesis of diverse heterocyclic compounds, including imidazo[1,2-a]pyridines and tetrazolo-fused benzodiazepines.
Dr. Frett's scholarship metrics include an h-index of 24, 136 total publications, and 1,489 total citations. He has collaborated with several researchers at the University of Arkansas for Medical Sciences, including Baku Acharya, Samantha Kendrick, Ying-Zhi Xu, and Mason McCrory.
Research Overview
Dr. Brendan Frett received his Ph.D. in Pharmaceutical Sciences with an emphasis in Drug Discovery and Development from the University of Arizona in 2014. He received postdoctoral training in Medicinal Chemistry as well as Pharmaceutics at the University of Arizona. Dr. Frett has successfully transferred academic-based discoveries to pharmaceutical companies for clinical development. He is interested in pursuing translational research projects, where research completed in his laboratory can directly help patients.
Metrics
- h-index: 24
- Publications: 136
- Citations: 1,491
Positions
-
Assistant Professor 2016–presentUniversity of Arkansas for Medical Sciences Pharmaceutical Science, College of Pharmacy Institutional directory
Selected Publications
-
Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer (2026)
-
Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high‐risk KMT2A ‐rearranged acute myeloid leukaemia (2025)
-
Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitors (2025)
-
Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors (2025)
-
Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral–obstructed mice (2025)
-
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present) (2025)
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
Epigenetic Dysregulation and Therapeutic Targeting of RET Receptor Tyrosine Kinase in High-Risk KMT2A-Rearranged Pediatric Acute Myeloid Leukemia (2025)
-
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)
-
Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4 (2024)
-
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
-
557 Dual TGFβR1/MAP4K4 inhibitor reduces kidney injury in a mouse model of renal fibrosis. (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer NIH Co-Investigator
- Center for Molecular Interactions in Cancer (CMIC) NIH Co-Investigator
Collaboration Network
Top Collaborators
Hongyu Li
The University of Texas at San Antonio Health Science Center (US)
27 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities
- The Exploration of Chirality for Improved Druggability within the Human Kinome
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
Showing 5 of 27 shared publications
Baku Acharya
University of Arkansas for Medical Sciences
18 shared publications
In database
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group
Showing 5 of 18 shared publications
Naga Rajiv Lakkaniga
Indian Institute of Technology Dhanbad (IN)
16 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- The Exploration of Chirality for Improved Druggability within the Human Kinome
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
Showing 5 of 16 shared publications
Debasmita Saha
Discovery Institute (US)
13 shared publications
- The Exploration of Chirality for Improved Druggability within the Human Kinome
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Intramolecular cyclization of imidazo[1,2- a ]pyridines via a silver mediated/palladium catalyzed C–H activation strategy
Showing 5 of 13 shared publications
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
12 shared publications
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
- Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
Showing 5 of 12 shared publications
Gunaganti Naresh
University of Arkansas for Medical Sciences
9 shared publications
In database
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
Showing 5 of 9 shared publications
Anupreet Kharbanda
University of Arkansas for Medical Sciences
9 shared publications
In database
- The Exploration of Chirality for Improved Druggability within the Human Kinome
- Catalyst free, C-3 functionalization of imidazo[1,2- a ]pyridines to rapidly access new chemical space for drug discovery efforts
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
- Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives
Showing 5 of 9 shared publications
Nicholas McConnell
University of California, San Francisco (US)
7 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
- Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT
- Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives
- Diversity‐Oriented Synthesis of Functionalized Imidazopyridine Analogues with Anti‐Cancer Activity through a Transition‐Metal Free, One‐pot Cascade Reaction
Showing 5 of 7 shared publications
Wei Yan
The University of Texas at San Antonio Health Science Center (US)
7 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- The Exploration of Chirality for Improved Druggability within the Human Kinome
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
- Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
- Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction
Showing 5 of 7 shared publications
Zhigang Xu
Chongqing University of Arts and Sciences (CN)
6 shared publications
- Recent advances in the development of polycyclic skeletons via Ugi reaction cascades
- Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells
- Diversity‐Oriented Synthesis of Functionalized Imidazopyridine Analogues with Anti‐Cancer Activity through a Transition‐Metal Free, One‐pot Cascade Reaction
- One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction
- Synthesis of Constrained Heterocycles Employing Two Post‐Ugi Cyclization Methods for Rapid Library Generation with In Cellulo Activity
Showing 5 of 6 shared publications
Francesca Carlomagno
CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) (IT)
6 shared publications
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
- Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
- Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Showing 5 of 6 shared publications
Daniel W. Armstrong
University of Arkansas for Medical Sciences
6 shared publications
In database
- FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)
Showing 5 of 6 shared publications
Maha Hanafi
Cairo University
6 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors
- Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitors
Showing 5 of 6 shared publications
Jie Lei
Chongqing University of Arts and Sciences (CN)
5 shared publications
- Recent advances in the development of polycyclic skeletons via Ugi reaction cascades
- Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells
- Diversity‐Oriented Synthesis of Functionalized Imidazopyridine Analogues with Anti‐Cancer Activity through a Transition‐Metal Free, One‐pot Cascade Reaction
- One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction
- Correction: One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction
Zhong‐Zhu Chen
Chongqing University of Arts and Sciences (CN)
5 shared publications
- Recent advances in the development of polycyclic skeletons via Ugi reaction cascades
- Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells
- Diversity‐Oriented Synthesis of Functionalized Imidazopyridine Analogues with Anti‐Cancer Activity through a Transition‐Metal Free, One‐pot Cascade Reaction
- One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction
- Correction: One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction
Similar Researchers
Based on overlapping research topics
Anupreet Kharbanda
University of Arkansas for Medical Sciences
Drug Discovery
Cancer Treatment and Pharmacology
Structure-Activity Relationship
Baha’a Jabali
University of Arkansas for Medical Sciences
Drug Discovery
Cancer Treatment and Pharmacology
Structure-Activity Relationship
Katie Rose Ryan
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Molecular Biology Techniques and Applications
Fengping Lv
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Drug Design
Gunaganti Naresh
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Molecular Biology Techniques and Applications
Emily Kanwischer
University of Arkansas for Medical Sciences
Drug Discovery
Cancer Treatment and Pharmacology